Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insys Therapeutics Inc. INSYQ

Healthcare Biotechnology
Insys Therapeutics Inc is a specialty pharmaceutical company. It develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients' quality of life. The company have two marketed products; SUBSYS, a proprietary sublingual fentanyl spray; and SYNDROS, a proprietary orally administered liquid formulation of dronabinol. The company derives... see more

Recent & Breaking News (OTCPK:INSYQ)

FDA Accepts New Drug Application for INSYS Therapeutics' Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose

GlobeNewswire July 3, 2019

INSYS Therapeutics, Inc. Receives Court Approval of "First Day" Motions

GlobeNewswire June 12, 2019

INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities

GlobeNewswire June 10, 2019

INSYS Therapeutics Reports First Quarter 2019 Results

GlobeNewswire May 10, 2019

INSYS Therapeutics Implements Leadership Changes

GlobeNewswire April 15, 2019

INSYS Therapeutics to Present Poster of Pharmacokinetic Study of Naloxone Novel Nasal Spray at The College on Problems of Drug Dependence Annual Scientific Meeting

GlobeNewswire March 25, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Benzinga.com  March 23, 2019

36 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  March 19, 2019

Mid-Afternoon Market Update: Crude Oil Up 2.6%; Synchronoss Technologies Shares Drop After Q4 Results

Benzinga.com  March 13, 2019

48 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  March 13, 2019

Analysts Positive On Insys Ahead Of 2019 Pipeline Catalysts

Benzinga.com  March 8, 2019

The Daily Biotech Pulse: Tonix Gets European Patent, EC Nod For Roche, Insys Earnings

Benzinga.com  March 8, 2019

INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results

GlobeNewswire March 7, 2019

INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7

GlobeNewswire March 6, 2019

INSYS Therapeutics Presented Poster of Initial Pharmacokinetic Study of Epinephrine Nasal Spray for the Emergency Treatment of Allergic Reactions (Type I) including Anaphylaxis at American Academy of Allergy, Asthma and Immunology Annual Meeting

GlobeNewswire February 25, 2019

26 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  February 11, 2019

INSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis

GlobeNewswire January 9, 2019

INSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2019

INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of Naloxone

GlobeNewswire December 18, 2018

INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology

GlobeNewswire December 17, 2018